| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/30/2013 | CN102895275A Red ginseng submicron powder and method for preparing same |
| 01/30/2013 | CN102895267A Preparation method of nodule tolypothrix total alkaloids extractive |
| 01/30/2013 | CN102895258A Pleurotus tuber-regium polysaccharide functionalized nanometer selenium hydrosol having anti-tumor activity and preparation method thereof |
| 01/30/2013 | CN102895252A Application of Houttuynoid A in drugs for treating lung cancer |
| 01/30/2013 | CN102895249A Application of Houttuynoid E to medicament for treating prostatic carcinoma |
| 01/30/2013 | CN102895248A Application of Houttuynoid A in drugs for treating laryngocarcinoma |
| 01/30/2013 | CN102895247A Application of Houttuynoid B to medicament for treating oophoroma |
| 01/30/2013 | CN102895225A Application of Aphanamixoid A to medicament for treating cholangiocarcinoma |
| 01/30/2013 | CN102895224A Application of Aphanamixoid A in drugs for treating breast cancer |
| 01/30/2013 | CN102895221A Target degradation Bcr-Abl protein reagent and application of target degradation Bcr-Abl protein reagent in preparing Philadelphia chromosome positive tumor treatment medicine |
| 01/30/2013 | CN102895216A Anti-cancer medicament silicon plastid microcapsule and preparation method thereof |
| 01/30/2013 | CN102895212A Dry pressed coating tablet containing tegafur, gimeracil and oteracil potassium |
| 01/30/2013 | CN102895199A Method for preparing microspheres through oil in nano-particle suspension and sustained-release microspheres |
| 01/30/2013 | CN102895197A Method for preparing microspheres through oil in nano-particle suspension-oil in oil and sustained-release microspheres |
| 01/30/2013 | CN102895195A Preparation method of 5-fluorouracil molecular surface imprinting microsphere |
| 01/30/2013 | CN102895184A Epirubicin hydrochloride injection |
| 01/30/2013 | CN102895183A Cabazitaxel for injection and preparation method thereof |
| 01/30/2013 | CN102895176A Method for preparing porous gel containing recombinant human endostatin |
| 01/30/2013 | CN102327615B Bone targeting vector and medicament |
| 01/30/2013 | CN102286055B B-drop-3, 6-disubstituted cholestane compound and preparation method and application thereof to preparation of antitumor drug |
| 01/30/2013 | CN102212067B Garcinia derivative, method for preparing same and pharmaceutical application thereof |
| 01/30/2013 | CN102204950B Method for extracting flavonoid from liquorice waste residue |
| 01/30/2013 | CN102180949B Polypeptide capable of specifically combining vessel endothelial growth factor and application thereof |
| 01/30/2013 | CN102172397B In vivo targeting of dendritic cells |
| 01/30/2013 | CN102146080B Beta-carboline alkali derivative compounds and application thereof |
| 01/30/2013 | CN102088983B Treatment of cancers of the blood using selected glycomimetic compounds |
| 01/30/2013 | CN101928740B MMP14 double-target efficient binding peptide, method for obtaining polypeptide structure sequence and application of target compound |
| 01/30/2013 | CN101896477B The five crystal forms of the nicousamide, the preparation methods, the pharmaceutical compositions and the uses thereof |
| 01/30/2013 | CN101879156B Medicinal composition and application thereof |
| 01/30/2013 | CN101849907B Nanoemulsion of N-[4-(2,4 dimethoxy phenyl)-5-oxygroup-4,5-dihydro-[1,2] disulfide group-[4,3-b]-6-pyrryl]-3,5-di-trifluoromethyl benzamide and preparation method thereof |
| 01/30/2013 | CN101687874B Pyrrolotriazine kinase inhibitors |
| 01/30/2013 | CN101683331B Application of alkannin derivant |
| 01/30/2013 | CN101671369B Phosphoryl methyl salinomycin ether derivative and preparation method thereof |
| 01/30/2013 | CN101591288B Cytochalasin compounds and preparation method and application thereof |
| 01/30/2013 | CN101590092B Traditional Chinese medicine combination for treating leukemia and preparation method thereof |
| 01/30/2013 | CN101559037B Binary solution type preparation for intravenous injection and intracerebral injection |
| 01/30/2013 | CN101481394B 2,3,4,6-tetra-O-acetyl-D-glucopyranosyl-[N,N'-bis(2-chloroethyl)]- phosphorodiamidate, and preparation and use thereof |
| 01/30/2013 | CN101189023B 监测和调制hgf/hgfr活性 Monitoring and modulation hgf / hgfr activity |
| 01/29/2013 | US8362241 Inhibitors of PI3 kinase and/or mTOR |
| 01/29/2013 | US8362236 Macrocyclic compound |
| 01/29/2013 | US8362231 RNA interference mediating small RNA molecules |
| 01/29/2013 | US8362205 Delocalization molecules and use thereof |
| 01/29/2013 | US8362023 Pyrazolo pyrimidines |
| 01/29/2013 | US8362014 ABT-263 crystalline forms |
| 01/29/2013 | US8362003 3-aminopyrrolidine derivatives as modulators of chemokine receptors |
| 01/29/2013 | US8361992 Complexes of 4-hydroperoxy ifosfamide as anti-tumor agents |
| 01/29/2013 | US8361978 Use of herpes vectors for tumor therapy |
| 01/29/2013 | US8361968 Metastin derivatives and use thereof |
| 01/29/2013 | US8361751 Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost |
| 01/29/2013 | US8361466 Tweak receptor |
| 01/29/2013 | US8361457 Duplexed parvovirus vectors |
| 01/29/2013 | US8361443 Peptide-based compounds |
| 01/29/2013 | CA2705481C Cephalomannine derivatives, their preparation, pharmaceutical composition and use thereof |
| 01/29/2013 | CA2584179C N,n'-diphenylurea derivatives which are suitable as kinase inhibitors |
| 01/29/2013 | CA2582174C 4-hydroxy tamoxifen gel formulations |
| 01/29/2013 | CA2541425C Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof |
| 01/29/2013 | CA2469310C Plasmid mediated supplementation for treating chronically ill subjects |
| 01/29/2013 | CA2459822C Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents |
| 01/29/2013 | CA2309652C Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
| 01/24/2013 | WO2013013240A2 Macrocyclic compounds and related compositons and methods of use |
| 01/24/2013 | WO2013013238A2 Compounds and related compositions and methods of use |
| 01/24/2013 | WO2013013195A1 Compositions and methods for treating polycythemia vera and essential thrombocythemia |
| 01/24/2013 | WO2013013075A2 Peptides shared among lethal cancers and therapeutic compositions comprising said peptides |
| 01/24/2013 | WO2013013061A1 Methods and compounds for treating cancer |
| 01/24/2013 | WO2013013038A2 Doping agents and polymeric compositions thereof for controlled drug delivery |
| 01/24/2013 | WO2013013031A1 Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase |
| 01/24/2013 | WO2013013003A1 Methods for treating inflamatory conditions and states, and cancers by antagonizing nf-kb activation |
| 01/24/2013 | WO2013012918A1 Heterocyclic compounds and uses thereof |
| 01/24/2013 | WO2013012894A1 Fty720 increases cd74 expression and sensitizes cancer cells to anti-cd74 antibody-mediated cell death |
| 01/24/2013 | WO2013012891A1 Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers |
| 01/24/2013 | WO2013012723A1 Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors |
| 01/24/2013 | WO2013012681A1 Tricyclic inhibitors of kinases useful for the treatment of proliferative diseases |
| 01/24/2013 | WO2013012648A1 Gdf15 in diagnostic and therapeutic applications |
| 01/24/2013 | WO2013012644A1 2-methylene-20(21)-dehydro-19,24,25,26,27,-pentanor-vitamin d analogs |
| 01/24/2013 | WO2013012628A2 Immune-stimulating photoactive hybrid nanoparticles |
| 01/24/2013 | WO2013012135A1 Pre-freeze dried azacitidine preparation, freeze dried azacitidine preparation and method of manufacturing the same |
| 01/24/2013 | WO2013011858A1 Tetravalent platinum complex and pharmaceutical composition containing same |
| 01/24/2013 | WO2013011841A1 Indirubin derivative having highly selective cytotoxicity for malignant tumors |
| 01/24/2013 | WO2013011506A1 Modified platinum compounds |
| 01/24/2013 | WO2013011033A1 3-(fluorvinyl)pyrazoles and the use thereof |
| 01/24/2013 | WO2013010869A1 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk-inhibitors |
| 01/24/2013 | WO2013010868A1 4 - imidazopyridazin- 1 -yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as btk- inhibitors |
| 01/24/2013 | WO2013010749A1 Sequential anti - ctla4 and targeted il-2 therapy |
| 01/24/2013 | WO2013010573A1 Compounds with matrix-metalloproteinase inhibitory activity |
| 01/24/2013 | WO2013010256A1 Combination treatment for cancer |
| 01/24/2013 | WO2012158880A3 Anaplastic thyroid cancers harbor novel oncogenic mutations of the alk gene |
| 01/24/2013 | WO2012135522A3 Process for manufacturing conjugates of improved homogeneity |
| 01/24/2013 | WO2012103226A3 Bendamustine formulations |
| 01/24/2013 | WO2012097371A3 Chemical inhibitors of cholesterol biosynthesis and venous angiogenesis |
| 01/24/2013 | US20130024956 Antibodies to cd40 |
| 01/24/2013 | US20130023714 Medical and Imaging Nanoclusters |
| 01/24/2013 | US20130023663 Substituted stilbenes and their reactions |
| 01/24/2013 | US20130023647 Modified human thymic stromal lymphopoietin |
| 01/24/2013 | US20130023587 Compositions and methods for the treatment of cancer |
| 01/24/2013 | US20130023580 Compositions and Methods for Inhibiting Expression of XBP-1 Gene |
| 01/24/2013 | US20130023578 siRNA for inhibition of c-Met expression and anticancer composition containing the same |
| 01/24/2013 | US20130023577 COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES |
| 01/24/2013 | US20130023574 Method for generating data set for integrated proteomics, integrated proteomics method using data set for integrated proteomics that is generated by the generation method, and method for identifying causative substance using same |
| 01/24/2013 | US20130023572 Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases |
| 01/24/2013 | US20130023567 Novel Compounds |